α-L-Ala-L-Pro-methyl ester | 81377-00-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: α-L-Ala-L-Pro-methyl ester
• 英文别名: Ala-Pro-OMe；L-Alanyl-L-proline methyl ester；methyl (2S)-1-[(2S)-2-aminopropanoyl]pyrrolidine-2-carboxylate
• CAS: 81377-00-6
• 化学式: C₉H₁₆N₂O₃
• 分子量: 200.238
• InChiKey: WKMFENXPTHYYIW-BQBZGAKWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  α-L-Ala-L-Pro-methyl ester 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 32.25h， 生成 H-Ala-Pro-Ala-Pro-OH
  参考文献：
  名称：

  Synthesis, DNA recognition and cleavage studies of novel tetrapeptide complexes, Cu(II)/Zn(II)-Ala-Pro-Ala-Pro

  摘要：

  New tetrapeptide complexes Cu(II)center dot Ala-Pro-Ala-Pro (1) and Zn(II)center dot Ala-Pro-Ala-Pro (2) were synthesized from the reaction of tetrapeptide, Ala-Pro-Ala-Pro and CuCl2/ZnCl2 and were thoroughly characterized by elemental analysis, IR, H-1 and C-13 NMR (in case of 2), ESI-MS, UV and molar conductance measurements. The solution stability study was carried out employing UV-vis absorption titrations over a broad range of pH which suggested the stability of the complexes in solution. In vitro interaction of complexes 1 and 2 with CT-DNA was studied employing UV-vis, fluorescence, circular dichroic and viscometry studies. To throw insight into molecular binding event at the target site, UV-vis titrations of 1 and 2 with mononucleotides of interest viz.; 5'-GMP and 5'-TMP were carried out. Cleavage activity of the complexes with pBR322 plasmid DNA was evaluated by agarose gel electrophoresis and, the electrophoresis pattern demonstrated that both the complexes 1 and 2 are efficient cleavage agents. Further, the Cu(II) complex displayed efficient oxidative cleavage of supercoiled DNA while various reactive oxygen species are responsible for the cleavage in Zn(II) complex. (c) 2013 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.saa.2013.01.059
• 作为产物：
  描述：

  L-脯氨酸甲酯 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 α-L-Ala-L-Pro-methyl ester
  参考文献：
  名称：

  用于二甲基锌对醛的对映选择性加成的二肽衍生催化剂的发现

  摘要：

  制备了一类新的模块化手性催化剂，这些催化剂来源于各种氨基酸-L-Pro 二肽，并测试了催化剂催化二甲基锌对芳香醛的对映选择性加成的能力。源自 L-Asp-L-Pro 的二肽被确定为在室温下添加的有效催化剂，效率高达 97:3，产率为 95%。

  DOI：

  10.1002/ejoc.201200063

文献信息

• Enantioselective Henry reaction catalyzed by C2-symmetric chiral diamine–copper(II) complex
  作者：Sermadurai Selvakumar、Dhanasekaran Sivasankaran、Vinod K. Singh

  DOI：10.1039/b904254g

  日期：——

  A copper(II) complex of C2-symmetric diamine has been proved to be an efficient catalyst for the enantioselective Henry reaction between nitroalkanes and various aldehydes to provide β-hydroxy nitroalkanes in high yields (up to 97%), moderate diastereoselectivities (up to 71:29) and excellent enantiomeric excesses (up to 96%). The chiral nitroaldol adduct obtained has been further converted into chiral

  事实证明，C 2对称二胺的铜（II）络合物是硝基链烷烃与各种醛之间对映选择性亨利反应的有效催化剂，以高产率（高达97％），中等非对映选择性（高达90％以上）提供β-羟基硝基链烷烃。至71:29）和出色的对映体过量（高达96％）。所获得的手性硝基醛醇加合物在几个步骤中已进一步转化为手性氮丙啶。
• Asymmetric Synthesis of 3,4,6-Trisubstituted 2,5-Diketopiperazines by Using Dynamic Kinetic Resolution of α-Bromo Tertiary Acetamides
  作者：Jinho Baek、Seock Yong Kang、Chan Im、Yong Sun Park

  DOI：10.1002/ejoc.201301936

  日期：2014.5

  A new and efficient method for the asymmetric synthesis of 3,4,6-trisubstituted 2,5-diketopiperazines has been developed. The dynamic kinetic resolution of L-amino-acid-derived α-bromo tertiary amides in the nucleophilic substitution reaction with p-anisidine and a subsequent deprotection-cyclization process provides rapid access to diverse cis-2,5-diketopiperazines 5a–5o and proline-containing trans-2

  已开发出一种新的有效方法，用于不对称合成 3,4,6-三取代 2,5-二酮哌嗪。L-氨基酸衍生的 α-溴叔酰胺在与对茴香胺的亲核取代反应和随后的脱保护环化过程中的动态动力学拆分提供了快速获得各种顺式 2,5-二酮哌嗪 5a-5o 和脯氨酸的途径- 含有对映异构纯形式的反式-2,5-二酮哌嗪 5p-5t，总产率为 45-67%。
• Solvent‐Driven Chiral‐Interaction Reversion for Organogel Formation
  作者：Guangyan Qing、Xingxing Shan、Wenrui Chen、Ziyu Lv、Peng Xiong、Taolei Sun

  DOI：10.1002/anie.201308554

  日期：2014.2.17

  For chiral gels and related applications, one of the critical issues is how to modulate the stereoselective interaction between the gel and the chiral guest precisely, as well as how to translate this information into the macroscopic properties of materials. Herein, we report that this process can also be modulated by nonchiral solvents, which can induce a chiral‐interaction reversion for organogel

  对于手性凝胶及其相关应用，关键问题之一是如何精确调节凝胶与手性客体之间的立体选择性相互作用，以及如何将此信息转化为材料的宏观特性。在本文中，我们报道该过程也可以通过非手性溶剂来调节，这可以诱导有机凝胶形成的手性相互作用的逆转。可以通过明显的胶凝速度差异和所得自组装的形态观察到这一过程。这种手性效应已成功应用于奎宁对映异构体的选择性分离，并赋予凝胶材料“聪明”的优点。
• Dipeptide derivative of fatty acid
  申请人：Suntory Limited

  公开号：US04772587A1

  公开（公告）日：1988-09-20

  A novel compound that exhibits inhibitory activity against prolyl endopeptidase and a method for chemical synthesis of said compound, as well as its use as a prolyl endopeptidase inhibitor and an anti-amnesic agent that contains said compound as the active ingredient are provided.

  本发明提供了一种新的化合物，该化合物具有抑制脯氨酰内切酶活性的作用，以及一种该化合物的化学合成方法，以及将该化合物用作脯氨酰内切酶抑制剂和抗遗忘剂的用途，其中该化合物为活性成分。
• NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES
  申请人：Botrous Iriny

  公开号：US20100249128A1

  公开（公告）日：2010-09-30

  The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.

  本发明涉及式（I）的化合物和药学上可接受的盐，其中X，R1，R2，R3，R4，R5，R6，R7和R8如上所定义。本发明还涉及包含该化合物和药学上可接受的盐的制药组合物以及治疗糖尿病及其并发症（尤其是糖尿病视网膜病变、肾病或神经病变）、癌症、缺血、炎症、中枢神经系统疾病、心血管疾病、阿尔茨海默病和皮肤病、病毒性疾病、炎症性疾病或肝脏是靶器官的疾病的治疗方法。